The immunogenicity of a single dose of hepatitis A virus vaccines (Havrix® and Epaxal®) in Korean young adults

• Published in: Yonsei medical journal Vol. 55; no. 1; pp. 126 - 131
• Main Authors: Lim, Jiseun, Song, Yeong-Jun, Park, Woong-Sub, Sohn, Haesook, Lee, Moo-Sik, Shin, Dong-Hoon, Kim, Chun-Bae, Kim, Hwasung, Oh, Gyung-Jae, Ki, Moran
• Format: Journal Article
• Language: English
• Published: Korea (South) Yonsei University College of Medicine 01-01-2014; 연세대학교의과대학
• Subjects: Adolescent; Adult; Female; Hepatitis A - immunology; Hepatitis A - prevention & control; Hepatitis A Vaccines; Hepatitis A Virus, Human - immunology; Hepatitis A Virus, Human - pathogenicity; Humans; Male; Original; Young Adult; 의학일반; hepatitis A vaccine; vaccine; Hepatitis A virus; immune; young adults
• ISSN: 0513-5796; 1976-2437
• DOI: 10.3349/ymj.2014.55.1.126

Assessing the immunogenicity of a single dose of hepatitis A virus (HAV) vaccines is important because some people receive only a single dose. However, previous studies have shown variable results and have not examined the effects of demographic characteristics other than gender. This study was performed to examine the immunogenicity of a single dose of HAV vaccine according to the vaccine type and demographic characteristics in young adults.
Seronegative medical school students were randomly allocated to receive either Havrix or Epaxal.
After approximately 11 months, the seroconversion rate in 451 participants was 80.7%. In men, the Havrix group showed a significantly higher seroconversion rate (81.9%) than the Epaxal group (69.2%), whereas both vaccine groups showed similarly high immunogenicity in women (Havrix: 90.1%, Epaxal: 92.9%; P for interaction=0.062). According to the results of a multivariate analysis, Epaxal showed significantly lower immunogenicity than Havrix only in men. Age, obesity, drinking, smoking, and follow-up time did not significantly affect seroconversion in either gender.
The seroconversion rate of single-dose HAV vaccines was low in men, particularly in those who received Epaxal. Our results suggest that gender effects should be considered when comparing the immunogenicity of different HAV vaccines.